德孚在中国

108139

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





QR Code

已发表论文

银屑病增加抗中性粒细胞胞浆抗体相关性血管炎的风险：一项倾向评分匹配研究的见解

 

Authors Cui R, Wang Q, Kang ZJ, Du Y, Chen M, Wang YH, Wei JC, Dai S 

Received 30 April 2025

Accepted for publication 10 September 2025

Published 26 September 2025 Volume 2025:14 Pages 1087—1095

DOI https://doi.org/10.2147/ITT.S527251

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Sarah Wheeler

Authors Cui R, Wang Q, Kang ZJ, Du Y, Chen M, Wang YH, Wei JC, Dai S 

Received 30 April 2025

Accepted for publication 10 September 2025

Published 26 September 2025 Volume 2025:14 Pages 1087—1095

DOI https://doi.org/10.2147/ITT.S527251

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Sarah Wheeler

atology and Immunology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan; 3Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan; 4Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan; 5Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan

*These authors contributed equally to this work

Correspondence: Sheng‐Ming Dai, Department of Rheumatology and Immunology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, Email shengmingdai@163.com James Cheng‐Chung Wei, Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, Email jccwei@gmail.com

Purpose: This study aimed to investigate the risk of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAVs) among patients with psoriasis in a large population.
Patients and Methods: In this population-based study using the collaborative electronic health record research network, the risk of developing AAVs (ie, eosinophilic granulomatosis with polyangiitis (EGPA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA)) was analyzed in a cohort of patients diagnosed with psoriasis between 2006 and 2024. Non-psoriasis controls were selected in a 1:1 ratio using propensity score matching. Patients who were diagnosed with AAVs before the index date were excluded. Univariate Cox proportional hazard model and subgroup analyses were used to estimate the hazard ratio (HR) with a 95% confidence interval (CI) for developing AAVs. The Kaplan-Meier method was used to plot the cumulative incidence curves. The risk of AAVs in psoriatic patients treated with biological agents was explored.
Results: After matching, 436,201 patients were included in each cohort. There were 281 incident cases of AAV during follow-up in the psoriasis cohort and 122 incident cases of AAV in the non-psoriasis cohort. The risk of developing AAVs in the psoriasis cohort was significantly higher than in the non-psoriasis cohort (HRs (95% CI) for AAVs, EGPA, and GPA were 2.01 (1.63 to 2.49), 1.84 (1.11 to 3.06), and 2.11 (1.65 to 2.71), respectively. Compared with psoriasis patients who did not receive biologics, those treated with biologics showed no statistically significant increase in AAVs risk (HR 1.31, 95% CI 0.65 to 2.66).
Conclusion: Patients with psoriasis have a higher risk of AAVs development. Treatment with biologic agents is not associated with an elevated risk of AAVs.

Keywords: psoriasis, anti-neutrophil cytoplasmic antibody, vasculitis, biological agents, incidence
Download Article[PDF]